LEMAITRE VASCULAR INC (LMAT): Results of Operations and Financial Condition
LEMAITRE VASCULAR INC (LMAT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d320964dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 LeMaitre Q2 2026 Financial Results BURLINGTON, MA, August 4, 2026 – LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q2 2026 results, announced a quarterly divid
How this was made
The 30-second read
Why it matters
The key tradable inputs are the reported Q2 financials (sales, gross margin, operating income, EPS) and the forward guidance ranges for sales, operating income, and EPS, alongside capital return (dividend) and liquidity (cash balance and repurchase authorization).
Market read
A single-company earnings and guidance disclosure with explicit ranges and capital return terms typically drives the next-session repricing and sets expectations for the upcoming quarter.
What to watch
Gross margin improvement is attributed to price, mix, and operational efficiencies; traders may scrutinize whether these drivers are repeatable in subsequent quarters, especially with headcount restraint already in place.
Background
This SEC 8-K (Item 2.02) reports LeMaitre Vascular’s Q2 2026 results, declares a quarterly dividend, and provides Q3, Q4, and full-year 2026 guidance.
Ticker impact
LeMaitre reported Q2 2026 sales of $70.4mm (+10%), EPS $0.74 (+23%), and issued Q3-Q4 and full-year guidance in the 8-K.
Likely positive bias for the stock into the next earnings window if investors view the guidance as credible and the Artegraft ramp as sustainable.
The release provides specific quarterly and full-year guidance ranges, plus margin and EPS directionality, and highlights Artegraft international approval expansion as a growth driver.
Market effects
Medical device peers may see read-across on vascular implant demand and margin durability, especially around Artegraft and international expansion.
EMEA and APAC both posted +18% growth in Q2, which can influence regional demand expectations for vascular device distributors.
International regulatory approvals (Arte graft now approved in 56 countries) reinforce the global commercialization narrative for vascular implants.
Counterpoint
Catheter sales declined 11% due to recall-driven overstocking in Q2 2025, so investors may discount near-term growth quality until normalization is clearer.
Key entities
- issuerLeMaitre Vascular, Inc.
Provider of vascular devices, implants, and services; reported Q2 2026 results and issued 2026 guidance in the 8-K.
- productArte graft
Internationally launched graft product; management states it is approved in 56 countries and drove growth in Q2.
- capital_returnQuarterly dividend
Board approved $0.25/share dividend payable September 3, 2026 to holders of record August 20, 2026.
- capital_returnShare repurchase program
Board authorized repurchase of up to $100.0mm, concluding February 18, 2027 unless extended.
